Počet záznamov: 1
everolimus
SYS d000068338 LBL 00000cz--a2200181n--4500 005 20250606221735.1 008 160101|||anznnbabn-----------|-a|a------ 040 $b slo $a BA006 $d BA006 $d BA006 065 $a D02.540.505.760.500 066 $a 01 $c 03 150 $a everolimus $x AA $x AD $x AE $x AG $x AI $x AN $x BL $x CF $x CH $x CL $x CS $x EC $x HI $x IM $x IP $x ME $x PD $x PK $x PO $x RE $x SD $x ST $x TO $x TU $x UR $2 slo 450 $w v $a Zortress $2 eng 450 $w v $a Zortress $2 slo 450 $w v $a 40-O-(2-hydroxyetyl)-rapamycín $2 slo 450 $w v $a Afinitor $2 slo 450 $w v $a Certican $2 slo 450 $w v $a RAD 001 $2 slo 450 $w v $a RAD001 $2 slo 450 $w v $a SDZ RAD $2 slo 450 $w v $a SDZ-RAD $2 slo 550 $7 sllk_us_auth*d007166 $Y Immunosuppressive Agents $w P $a imunosupresíva 550 $7 sllk_us_auth*d000091203 $Y MTOR Inhibitors $w P $a MTOR inhibítory 665 $a 2016 (1997) $2 eng 680 9-
$i A derivative of sirolimus and an inhibitor of TOR SERINE-THREONINE KINASES. It is used to prevent GRAFT REJECTION in heart and kidney transplant patients by blocking cell proliferation signals. It is also an ANTINEOPLASTIC AGENT. $2 eng 750 -2
$a Everolimus $2 eng 980 $x M
Počet záznamov: 1